Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) – Equities researchers at Jefferies Financial Group issued their Q1 2023 earnings per share estimates for Seres Therapeutics in a research note issued to investors on Tuesday, March 7th. Jefferies Financial Group analyst C. Howerton anticipates that the biotechnology company will post earnings per share of ($0.48) for the quarter. The consensus estimate for Seres Therapeutics’ current full-year earnings is ($0.98) per share. Jefferies Financial Group also issued estimates for Seres Therapeutics’ Q3 2023 earnings at ($0.14) EPS, Q4 2023 earnings at ($0.10) EPS, FY2023 earnings at ($0.88) EPS, FY2024 earnings at ($1.19) EPS and FY2025 earnings at ($0.42) EPS.
Several other equities analysts have also issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Seres Therapeutics in a research note on Wednesday. Piper Sandler lifted their target price on Seres Therapeutics from $9.00 to $13.00 in a research note on Thursday, December 8th. Canaccord Genuity Group cut their target price on Seres Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Chardan Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Seres Therapeutics in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Seres Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $15.25.
Seres Therapeutics Price Performance
Institutional Trading of Seres Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in MCRB. Flagship Pioneering Inc. lifted its stake in Seres Therapeutics by 60.8% during the 3rd quarter. Flagship Pioneering Inc. now owns 23,117,045 shares of the biotechnology company’s stock worth $148,411,000 after acquiring an additional 8,738,243 shares in the last quarter. FMR LLC lifted its position in Seres Therapeutics by 34.0% during the 2nd quarter. FMR LLC now owns 18,601,212 shares of the biotechnology company’s stock worth $63,802,000 after acquiring an additional 4,723,347 shares during the period. Federated Hermes Inc. lifted its holdings in shares of Seres Therapeutics by 2.9% in the 3rd quarter. Federated Hermes Inc. now owns 18,499,136 shares of the biotechnology company’s stock valued at $118,765,000 after buying an additional 516,880 shares during the period. Vanguard Group Inc. increased its stake in Seres Therapeutics by 24.0% in the 3rd quarter. Vanguard Group Inc. now owns 6,610,856 shares of the biotechnology company’s stock valued at $42,442,000 after purchasing an additional 1,280,039 shares in the last quarter. Finally, BlackRock Inc. increased its stake in Seres Therapeutics by 9.4% in the 3rd quarter. BlackRock Inc. now owns 6,300,350 shares of the biotechnology company’s stock valued at $40,450,000 after purchasing an additional 539,617 shares in the last quarter. 90.16% of the stock is currently owned by hedge funds and other institutional investors.
About Seres Therapeutics
Seres Therapeutics, Inc engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
- Get a free copy of the StockNews.com research report on Seres Therapeutics (MCRB)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.